Cotadutide vs Dulaglutide
Head-to-head comparison of Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) and Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cotadutide | Dulaglutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist | Recombinant GLP-1 receptor agonist Fc fusion protein |
| Molecular Weight | ~4,700 Da | ~63,000 Da |
| Half-Life | Approximately 24 hours | About 5 days |
| Amino Acids | 37 | N/A |
| Typical Dose | 0.3-3 mg daily in clinical studies | 0.75-4.5 mg weekly |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 18 | 700 |
| Research Status | Clinical | Approved |
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Dulaglutide Benefits
- ✓modest weight loss
- ✓lower A1c
- ✓weekly dosing convenience
- ✓cardiometabolic benefit
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Dulaglutide Dosing
0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Dulaglutide Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠injection-site reactions
Research Overview
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Dulaglutide
Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.